Ptc Therapeutics, Inc. Earnings

Ptc Therapeutics, Inc.’s revenue jumped 459.73% since last year same period to $1176.1Mn in the Q1 2025. On a quarterly growth basis, Ptc Therapeutics, Inc. has generated 451.71% jump in its revenue since last 3-months.

Ptc Therapeutics, Inc.’s net profit jumped 1046.28% since last year same period to $866.56Mn in the Q1 2025. On a quarterly growth basis, Ptc Therapeutics, Inc. has generated 1415.24% jump in its net profits since last 3-months.

Ptc Therapeutics, Inc.’s net profit margin jumped 269.06% since last year same period to 73.68% in the Q1 2025. On a quarterly growth basis, Ptc Therapeutics, Inc. has generated 338.39% jump in its net profit margins since last 3-months.

Ptc Therapeutics, Inc.’s price-to-earnings ratio after this Q1 2025 earnings stands at 7.54.

Ptc Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -1.05 - a -48.94% fall from last quarter’s estimates.

Ptc Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -1.05.

Ptc Therapeutics, Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q2 2025. This indicates that the Ptc Therapeutics, Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.